Ignet
v2.0 Sign In

Gene Pair Information

Gene Pair: PALB2, BRCA1

Related Sentences

# PMID Sentence
1 33426465 Patients (N=37 349) had RS results of whom 714 had <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, or Lynch syndrome (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>) PVs.
2 33426465 For women aged 50 years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (≥26) with <i>BRCA1</i> (71.7% vs 14.4% with none; <i>P</i> &lt;.001), <i>PALB2</i> (37.1%; <i>P</i> = .001), and <i>BRCA2</i> (44.3%; <i>P</i> &lt; .001) PVs.
3 33426465 PVs in <i>BRCA1</i>, but not <i>BRCA2</i>, <i>PALB2</i>, <i>ATM</i>, <i>CHEK2</i>, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (<i>P</i> &lt; .001).
4 33724863 We used panel sequencing containing 22 high/moderate-risk susceptibility genes and parallel MLPA analysis of BRCA1/2, CHEK2 genes, to analyze 94 individuals with a strong family/personal history of breast and/or ovarian cancer.
5 33724863 In total, we have identified 22 causal DNA variants (23.4%) showing 15 primary findings in BRCA1/2 genes (68.2%) and 7 positive secondary findings in CHEK2, PALB2, CDH1, and MUTYH genes (31.8%).
6 33724863 Besides known mutations, the BRCA1 variant c.2794del (p.Val932Leufs*68) and variant c.2480dup (p.Tyr827*) in the CDH1 gene represent the novel, previously unpublished variants that might be population-specific.
7 34606975 Hereditary breast and ovarian cancer (HBOC) is a syndrome defined by an increased risk of developing breast and/or ovarian cancer most commonly due to germline disease-causing variants in the BRCA1 and BRCA2 genes, but also other causative genes such as PALB2, ATM and CHEK2.
8 34933735 Also, MLH3 is a DNA mismatch repair gene and mutation in this gene is harmful in different cancers.
9 34933735 We identified 26 variants in breast cancer patients, 22 inherited variants were found in MLH3, CHECK2, BRCA1, BRCA2, BLM, TP53, MSH6, NBN and PTEN genes and 4 somatic variants were found in PALB2, RAD50 and RBM10 genes.
10 35293552 The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1.
11 35293552 The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively).
12 35293552 The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98).
13 35293552 The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients.
14 37851290 Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
15 38248108 Counselling Framework for Germline <i>BRCA1/2</i> and <i>PALB2</i> Carriers Considering Risk-Reducing Mastectomy.
16 38248108 Female <i>BRCA1/2</i> and <i>PALB2</i> germline pathogenic variant carriers have an increased lifetime risk of breast cancer and may wish to consider risk-reducing mastectomy (RRM) for surgical prevention.